You are here

Esperion

Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers

BioSpace

Mon, 11/15/21 - 11:55 pm

PCSK9 inhibitors

Fortunes diverge for solo drug launchers

EP Vantage

Tue, 05/11/21 - 11:01 am

Intra-Cellular Therapies

Horizon Therapeutics

Karyopharm Therapeutics

Blueprint Medicines

Aurinia Pharmaceuticals

Global Blood Therapeutics

Esperion strikes Japan deal for 'goldilocks' cholestrol drug, bags $60M cash as pandemic forces virtual US rollout

Endpoints

Mon, 04/20/20 - 10:37 am

Covid-19 adds a new danger to drug launches

EP Vantage

Fri, 04/17/20 - 10:46 am

ACC: Esperion's Nexletol busts cholesterol levels regardless of statin, ezitimibe therapy

Fierce Pharma

Sat, 03/28/20 - 11:37 pm

clinical trials

c-reactive protein

Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter

Fierce Pharma

Fri, 01/3/20 - 11:03 pm

Horizon Therapeutics

Experion’s Cholesterol Drug Looks Great in Phase III, but Faces Tough Market

BioSpace

Tue, 03/19/19 - 11:30 am

clinical trials

American College of Cardiology

ACC 2019 preview – Bayer hopes for heart failure panache

EP Vantage

Tue, 03/12/19 - 10:15 am

Esperion shares bounce up on an effective triplet approach to slashing LDL

Endpoints

Tue, 08/8/17 - 10:06 am

LDL cholesterol

If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy

Motley Fool

Fri, 06/23/17 - 10:49 am

Esperion beefs up late-stage cholesterol program

BioPharma Dive

Sat, 10/15/16 - 12:25 pm

Biogen And Four Other Biotech Stocks Worth Watching

Forbes

Sat, 10/10/15 - 09:12 am

Clovis Oncology

Esperion cholesterol drug succeeds mid-stage study

Yahoo/Reuters

Tue, 03/17/15 - 07:14 pm

In Moribund Cholesterol Field, A New Drug Emerges

Forbes

Thu, 04/25/13 - 09:27 am

Pfizer's $1.3B Esperion Loss Contained a $426M Tax Win

BNET Pharma

Mon, 01/4/10 - 09:19 am